Bone Loss After Denosumab: Only Partial Protection with Zoledronate
Sign Up to like & getrecommendations! Published in 2017 at "Calcified Tissue International"
DOI: 10.1007/s00223-017-0288-x
Abstract: A case series of six women with postmenopausal osteoporosis who had received continuous denosumab for 7 years and were then given a single infusion of zoledronate (5 mg) is reported. During denosumab treatment, bone mineral density (BMD)… read more here.
Keywords: zoledronate; treatment; bmd; bone ... See more keywords